Resources
Clinical tools, implementation guides, and an ROI calculator — free for pharmacy professionals.
Downloadable Resources
Fill out the form below to unlock all resources instantly.
Vancomyzer Clinical Quick-Reference Card
A 1-page dosing reference card covering the Colin 2019 model parameters, AUC₂₄ target range, safety guardrails, and key workflow steps. Print it and keep it at your workstation.
2020 Vancomycin Guidelines Implementation Checklist
Step-by-step checklist for pharmacy directors implementing AUC-guided vancomycin monitoring. Covers P&T committee approval, staff training, protocol updates, software selection, and outcome tracking.
Vancomyzer vs. Competitors: Feature Comparison Matrix
Detailed side-by-side comparison of AUC-guided dosing tools across transparency, cost, model validation, features, regulatory classification, and support. Data-driven, not salesy.
Hospital Pilot Program Information Packet
Everything you need to present the Vancomyzer™ 90-day pilot to your leadership: program overview, what’s included, outcome metrics, timeline, and next steps.
ROI Calculator
How much could your hospital save by switching from trough-based to AUC-based vancomycin monitoring?
Your Hospital
Methodology:Projected AUC-guided VIN rate is calculated from your trough rate using the odds ratio of 0.625 (95% CI 0.469–0.834) from Abdelmessih et al. 2022 (Pharmacotherapy), a meta-analysis of 10 studies with 4,231 patients. Cost per AKI episode set at $15,000 (midpoint of $10K–$30K reported in vancomycin AKI cost analyses). Estimates are illustrative; actual savings depend on case mix, implementation fidelity, and concomitant nephrotoxin exposure.
Projected Impact
Vancomycin patients / year
300
Current AKI episodes / year
15% nephrotoxicity rate
45
Projected AKI episodes / year
9.9% with AUC-guided (OR 0.625, Abdelmessih 2022)
30
AKI episodes prevented
15
Estimated Annual Savings
$225,000
15fewer AKI episodes × $15,000 per episode
Supporting Literature
- Abdelmessih E, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis. Pharmacotherapy. 2022;42(9):741–753. doi:10.1002/phar.2722 — Source of OR 0.625 (95% CI 0.469–0.834); 10 studies, 4,231 patients.
- Rybak MJ, et al. Therapeutic monitoring of vancomycin for serious MRSA infections: A revised consensus guideline. Am J Health-Syst Pharm. 2020;77(11):835–864. doi:10.1093/ajhp/zxaa036 — Establishes AUC24400–600 mg·h/L target.
- Lodise TP, et al. Relationship between vancomycin trough concentrations and nephrotoxicity. Antimicrob Agents Chemother. 2008;52(4):1330–1336. doi:10.1128/AAC.01602-07 — Trough ≥ 15 mg/L associated with ~12–20% nephrotoxicity baseline.
- Carland JE, et al. Economic evaluations of TDM interventions in acute hospital settings: A systematic review. Br J Clin Pharmacol. 2024. doi:10.1111/bcp.16164 — Cost basis for $10K–$30K per AKI episode range.